Catalyst Brief

← Calendar

Readoutin 135d

Sanofi — Isatuximab SAR650984

Phase 3 primary completion: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant.

Date
Apr 2027
Type
Readout
Indication
Plasma Cell Myeloma

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sanofi

  1. May2027
  2. Nov2026